Apellis Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Biogen Inc. has finalized its acquisition of Apellis Pharmaceuticals, Inc. through a tender offer and subsequent merger, marking an exit filing for Biogen.
NASDAQ
Biogen Inc. announced its definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right (CVR) per share, valuing the company at approximately $41 billion.